/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Grace Therapeutics Inc share price today is $4.2, up 2.78%. The stock opened at $4.115 against the previous close of $3.95, with an intraday high of $4.6138 and low of $4.

style

pb-0

Grace Therapeutics Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$4.2 0.0278(2.78%) GRCE at 13 Mar 2026 01:22 PM Biotechnology

Lowest Today 4

Highest Today 4.6138

Today’s Open 4.115

Prev. Close 3.95

52 Week High 4.65

52 Week Low 1.75

Day’s Range: Low 4 High 4.6138

52-Week Range: Low 1.75 High 4.65

Grace Therapeutics Inc Institutional Holdings

Grace Therapeutics Inc Market Status

Strong Buy: 2

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Grace Therapeutics Inc Fundamentals

Market Cap 59.94 M

PB Ratio 0.9419

PE Ratio 0.0

Enterprise Value 38.12 M

Total Assets 71.99 M

Volume 2174173

Grace Therapeutics Inc Company Financials

Annual Revenue FY25:0 0.0M, FY24:0 0.0M

Annual Profit FY25:-7000 -0.0M, FY24:null 0.0M

Annual Net worth FY25:-9568000 -9.6M, FY24:-12853000 -12.9M

Quarterly Revenue Q4/2025:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:8000 0.0M, Q4/2024:0 0.0M

Quarterly Profit Q4/2025:-4116 -0.0M, Q3/2025:-2000 -0.0M, Q2/2025:-2000 -0.0M, Q1/2025:-2000 -0.0M, Q4/2024:null 0.0M

Quarterly Net worth Q4/2025:-3176480 -3.2M, Q3/2025:-938000 -0.9M, Q2/2025:-3362000 -3.4M, Q1/2025:636000 0.6M, Q4/2024:-4155000 -4.2M

About Grace Therapeutics Inc & investment objective

Company Information Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Organisation Biotechnology

Employees 6

Industry Biotechnology

CEO Mr. Prashant Kohli

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*